ETV6 (also known as TEL) encodes a transcriptional repressor in the ETS family 3 . ETV6 was initially identified as a tumor suppressor by its involvement in somatic translocations in childhood leukemia, including in ETV6-RUNX1 fusion. These translocations often occur together with a somatic mutation in the intact ETV6 allele, suggesting that loss of ETV6 function contributes to the development of leukemia [4] [5] [6] . Somatic ETV6 mutations have also been described in patients with MDS and T cell leukemias 7, 8 , but germline mutations had not been described until recently 9 . ETV6 also has a key role in hematopoiesis, as demonstrated in animal models 10, 11 . Mice with conditional Etv6 knockout in megakaryocytic-erythroid cells are thrombocytopenic, and megakaryocyte colony formation is absent in homozygous knockout hematopoietic cells and decreased in heterozygous knockout cells, indicating the involvement of Etv6 in thrombopoiesis 12, 13 . ETV6 is also one of four transcription factors shown to be sufficient to differentiate mouse fibroblasts into hematopoietic-lineage cells 14 .
We present here three families with germline mutations in ETV6 and defects in hematopoiesis. Affected members (n = 5) in the original family from the United States (family 1; Fig. 1a ) had variable thrombocytopenia (67,000-132,000 platelets/µl, normal range 150,000-450,000 platelets/µl) and elevated red blood cell MCV (92.5-101.5 fl, normal range 80-95 fl), suggesting a defect affecting megakaryocytic-erythroid precursors. Hematocrit and other hematologic indexes were within normal ranges (Supplementary Table 1) . Platelets had normal mean volume and ultrastructure, with some elongated α-granules (Supplementary Fig. 1 ). Patients exhibited Germline mutations in ETV6 are associated with thrombocytopenia, red cell macrocytosis and predisposition to lymphoblastic leukemia l e t t e r s mild to moderate bleeding, and two developed B cell-precursor ALL at ages 3 (III-1) and 37 (II-7) years. Histopathological analysis of bone marrow from affected individuals without leukemia showed small, hypolobulated megakaryocytes and abnormal red blood cell precursors (Fig. 1b) .
Whole-exome sequencing of family 1 identified a heterozygous single-nucleotide change in ETV6, which segregated completely with thrombocytopenia and high red blood cell MCV. This missense variant, c.641C>T, encodes a proline-to-leucine amino acid change (p.Pro214Leu) in the central domain of ETV6 (NM_001987, P41212) (Fig. 1c) ; the variant was not found in the 1000 Genomes Project or dbSNP databases and was predicted to be possibly damaging by PolyPhen-2. We screened 23 additional European families with autosomal dominant thrombocytopenia, high red blood cell MCV and, in some cases, increased incidence of leukemia via Sanger sequencing of the exons and exon-intron boundaries of ETV6. This approach led to the identification of two additional families with germline ETV6 mutations. One (family 2; Fig. 1a ) had affected members with platelet counts of 44,000-115,000 platelets/µl, red blood cell MCV of 88-97 fl and ALL in individual I-2 at age 14 years, with all affected members exhibiting a c.641C>T mutation identical to the one identified in family 1. In the other family (family 3; Fig. 1a) , having individuals with platelet counts of 99,000-101,000 platelets/µl and red blood cell MCV of 93-98 fl but no malignancies, we detected a mutation affecting the DNA-binding domain (c.1252A>G; p.Arg418Gly) that was not observed in the 1000 Genomes Project database and was predicted to be highly damaging by PolyPhen-2. Sequence alignment demonstrated that both mutations affect amino acids that are highly conserved across multiple species (Supplementary Note). Both mutations were present in the Catalogue of Somatic Mutations in Cancer (COSMIC) database, indicating that somatic acquisition of these mutations may be oncogenic.
The c.1252A>G mutation is located in the last codon of exon 7, which is split with exon 8, raising the possibility of this variant disrupting a splice site. To test this possibility, we isolated RNA from the peripheral blood cells of two individuals with the c.1252A>G mutation. RT-PCR detected two different transcripts, one of the expected size (386 bp) and another of 285 bp, indicating an alternatively spliced product (Supplementary Fig. 2) . Sequencing of the 285-bp product showed skipping of exon 7. This c.1153_1253del mutation is predicted to cause a partial deletion of the putative DNA-binding domain (p.385_418del) and a subsequent p.Asn385Valfs*7 frameshift alteration resulting in the introduction of a premature stop codon, raising the possibility of a truncated protein. Although this truncated protein was expressed in transfection assays in HEK293T cells (Supplementary Fig. 3) , it was not detected in platelets obtained from patients ( Supplementary Fig. 4 ), suggesting that it is not functional in megakaryocytes. The alternative splicing event did not affect all mutant RNA, as sequencing of the 386-bp RT-PCR product, as well as plasmids into which this product was cloned, showed the presence of the G nucleotide in addition to the wild-type A nucleotide, indicating that the Arg418Gly form of ETV6 is likely to be expressed in patients from this family. This type of genetic aberration, in which an exonic mutation creates an alternative splicing site as well as an amino acid change, has been observed in other hematological disorders such as hemoglobin E disease 15 .
ETV6 is a 57-kDa protein with 452 amino acids and 3 functional domains: the N-terminal pointed (PNT), central regulatory and C-terminal DNA-binding (ETS) domains (Fig. 1c) . The nuclear localization and transcriptional repression activity of ETV6 require homodimerization via the pointed domain 16 . ETV6 modulates the activity of other ETS transcription factors such as FLI1-for which hemizygous deletions of the corresponding gene cause ParisTrousseau-related thrombocytopenia 17, 18 -and several other known ETV6 interaction partners that are present in platelets 19, 20 and To investigate the effect of the p.Pro214Leu, p.Arg418Gly and p.385_418del alterations on ETV6 transcriptional repression, we used an in vitro reporter assay to measure luciferase expression induced by the promoter of the known ETV6 target stromelysin-1 (MMP3) 8, 22 . As expected, wild-type ETV6 repressed luciferase expression in comparison to empty vector. Expression of each of the three mutant forms of ETV6 resulted in less transcriptional repression than detected with wild-type ETV6 when the mutant was expressed alone or together with wild-type ETV6 (Fig. 1d) . We determined that the protein expression of wild-type ETV6 and all the mutants in transfected cells was equivalent by immunoblot, suggesting that the mutations do not influence protein stability (Supplementary Fig. 3 ).
Thrombopoiesis involves a complex sequence of cellular events in bone marrow megakaryocytes culminating in the elaboration of proplatelet extensions that release platelets into the circulation. Approximately 1 × 10 11 platelets must be produced daily to maintain the normal concentrations of 150-400 × 10 9 platelets/l in human blood 23 . To determine the effect of the p.Pro214Leu and p.Arg418Gly ETV6 substitutions on megakaryocyte differentiation, we transduced human CD34 + cells with lentivirus containing ETV6 alleles encoding wild-type, Pro214Leu or Arg418Gly protein and cultured them with thrombopoietin to support megakaryocyte development. Cells transduced with lentivirus expressing Pro214Leu or Arg418Gly ETV6 showed delayed/decreased maturation when compared to control cells and those transduced with lentivirus expressing wild-type ETV6, as indicated by increased numbers of small, immature megakaryocytes (similar to the abnormalities observed in the bone marrow of affected individuals; Fig. 1b ) and decreased generation of proplatelets ( Fig. 2a-d) . These findings indicate that the identified mutations affect megakaryocyte development and likely platelet production.
As ETV6 requires dimerization to exert its transcriptional repression, it is possible that the p.Pro214Leu, p.Arg418Gly and p.385_418del alterations might affect this interaction in a dominantnegative manner. We found that all mutants dimerized with wild-type ETV6, as demonstrated by concomitant pulldown of both differentially His-tagged wild-type ETV6 and Myc-tagged ETV6 mutants (Supplementary Fig. 5) . We examined the intracellular distribution of protein produced by transduced constructs for the Pro214Leu, Arg418Gly and wild-type forms of ETV6 in megakaryocytes by immunofluorescence staining for their Myc tag, which showed the expected nuclear localization for wild-type ETV6, whereas Pro214Leu and Arg418Gly ETV6 were concentrated in the cytoplasm (Supplementary Fig. 6 ). Staining for ETV6 (Fig. 3) showed that this protein was concentrated in the nuclei of untransduced controls and cells transduced with wild-type ETV6 and that it was largely in the cytoplasm of cells expressing mutant ETV6 (see also Supplementary  Videos 1-4) . These results indicate that the mutant forms of ETV6 [4] [5] [6] . To identify additional genetic aberrations contributing to leukemogenesis, we performed whole-exome and RNA sequencing (RNA-seq) on leukemia blast cells collected at the time of diagnosis and on bone marrow cells collected after remission in the same patient (III-1, family 1) . RNAseq showed that the wild-type ETV6 allele was structurally normal and that wild-type transcripts and those encoding p.Pro214Leu were expressed at equal levels in the bone marrow samples. We found several genetic variants and a new gene fusion between PAX5 and SHB in the leukemia sample that were not present in the remission sample (Supplementary Table 2 ). These variants may represent candidate mutations cooperative with the germline ETV6 mutation in the development of leukemia 24, 25 .
In summary, we present new germline mutations in ETV6, a gene known to be involved in human leukemogenesis and in mouse and zebrafish hematopoiesis, in three families with thrombocytopenia and high red blood cell MCV, along with leukemia predisposition in two of the three families (with the mutation encoding p.Pro214Leu). These mutations partially disrupt ETV6 transcriptional repression in vitro and cause aberrant cytoplasmic localization of both mutant and endogenous ETV6, suggesting a dominant-negative effect. Recently, while this manuscript was under review, a manuscript by Zhang et al. showed similar findings in three unrelated families 9 . These two studies represent effective independent replications and lend further support to the findings. The identified mutations in ETV6 also impair megakaryocyte development and proplatelet formation in culture. Furthermore, platelet RNA-seq of patients with the p.Pro214Leu alteration showed decreased expression of platelet-specific transcripts associated with the mutation, including considerable reduction in the levels of several cytoskeletal transcripts ( Supplementary  Figs. 7 and 8, Supplementary Note and Supplementary Data Set) . The mutations in these families show the implications of viable germline mutations in ETV6 and provide insights into the importance of ETV6 for platelet biology and tumor-suppressor activity.
METhODS
Methods and any associated references are available in the online version of the paper.
Accession codes. BioProject, PRJNA276621; Sequence Read Archive (SRA), SRP056053; database of Genotypes and Phenotypes (dbGaP), phs000873.v1.p1.
Note: Any Supplementary Information and Source Data files are available in the online version of the paper.
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ONLINE METhODS
Patient tissue acquisition. All patients in the original cohort (family 1) were recruited at the Hematology Clinic at the Children's Hospital of Michigan. The study received institutional review board approval from the University of Colorado Anschutz Medical Campus, and informed consent was obtained for all participants. Patients in families 2 and 3 were recruited in clinical centers in the Czech Republic and Italy as part of a European consortium focused on inherited platelet disorders. The institutional review board of the IRCCS Policlinico San Matteo Foundation of Pavia, Italy, approved the study protocol. Informed consent was obtained from all patients in the study. Studies were performed in accordance with the Declaration of Helsinki. Genomic DNA was extracted from whole blood using the Gentra PureGene DNA Extraction kit (Qiagen). Platelets were purified from whole blood and negatively selected using CD45 + MACS MicroBeads (Miltenyi Biotec). Bone marrow aspirates were obtained at diagnosis, and permission was obtained from families to use images.
Exome sequencing. Genomic DNA (3-5 µg) was sheared, size selected (~400-600 bp), ligated to sequencing adaptors and PCR amplified following standard library preparation procedures. The library obtained after PCR amplification was used for exome capture with the Agilent SureSelect Human All Exon v4 Capture kit. Eight exome-enriched samples were sequenced using two lanes (2 × 100 bp) on an Illumina HiSeq 2000. Exome sequencing was performed in eight individuals from family 1: II1, II3, II5, II7, III1, III2, III9 and III10. We screened for ETV6 mutations in the European families by Sanger sequencing of the promoter region, exons and exon-flanking regions of ETV6.
Bioinformatics of exome sequencing. Reads passing the Illumina chastity filter were subjected to a quality filter step that removed low-quality bases from the 3′ end and retained pairs of reads if the trimmed reads for both members of the pair were 50 bp or longer. Paired reads that passed the quality filter step were mapped to the reference human genome sequence (hg19) with GSNAP (Genomic Short-read Nucleotide Alignment Program, version 2012-07-20) 26 . Sequence calls for SNPs and insertions and deletions (indels) were performed using GATK (the Broad Institute's Genome Analysis Toolkit, v2.1-8-g5efb575) 27 .
The program ANNOVAR (Annotate Variation, version 2012-03-08) was used to classify variants and to cross-reference all variants across various genetic variation databases. Included in ANNOVAR are databases to identify nonsynonymous and splice-site variants (refGene.txt), variants in conserved genomic regions (phastConsElements46way.txt), variants in segmental duplications (genomicSuperDups.txt) and variant frequencies from the 1000 Genomes Project database (hg19_ALL.sites.2012_02.txt). Variants located outside of conserved regions or with frequencies >1% were excluded from further analysis 28 . Only nonsynonymous changes (SNPs and indels), splice-site variants and/or changes resulting in an aberrant stop codon were considered for further analysis. All insertion and deletion variants were considered to be damaging, whereas SNP variants were cross-referenced to dbNSFP (database of functional predictions for nonsynonymous SNPs, version 2.0) to determine whether the changes would be considered tolerable or damaging using four algorithms (Sorting Intolerant From Tolerant (SIFT), PolyPhen-2 (Polymorphism Phenotyping v2), likelihood-ratio test (LRT) and MutationTaster) 29 .
The final filtered list of variants for each affected family member was then intersected to find putative causal variants.
Platelet RNA sequencing. RNA was isolated from leukoreduced platelet preparations stored in TRIzol as previously described 30 . RNA-seq libraries were prepared and barcoded using Illumina TruSeq V2 with oligo(dT) selection. We generated 50 cycles of single-end reads on a single lane of the HiSeq 2000 and aligned the reads using Novoalign (Novocraft Technologies) to UCSC genome version hg19 with known and shuffled splice junctions included. Normalization of read counts and differential expression analysis were performed with DESeq2 (ref. 31) . Sample-to-sample variability in the levels of leukocyte transcripts, which can significantly alter read counts (J.W.R., unpublished observations), was corrected for by including the ratio of PTPRC (encoding the leukocyte marker CD45) to ITGA2B (encoding a platelet marker) as a factor in the model for significance testing. Relationship to the affected individual was also included in the model. Euclidean distance computation, clustering (complete linkage) and heat map analysis of the regularized logtransformed read counts was performed in R as described in the DESeq2 vignette. A list of 351 expressed transcripts involved in platelet biogenesis or function was curated from Reactome and from transcripts enriched in platelets in comparison to all other tissues in Illumina's Human Body Map 2.0. Gene Set Enrichment Analysis (GSEA) 32 of the 177 differentially expressed targets included testing against GO biological process, Biocarata, KEGG and Reactome gene sets.
